Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 7156 to 7170 of 7963 results

  1. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development [GID-TA11165] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

    In development [GID-TA11582] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development [GID-TA11086] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development [GID-TA10899] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]

    In development [GID-TA10930] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    Discontinued [GID-TA11033]

    Technology appraisal guidance
    Discontinued

  8. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    Discontinued [GID-TA10933]

    Technology appraisal guidance
    Discontinued

  9. Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]

    Discontinued [GID-TA11034]

    Technology appraisal guidance
    Discontinued

  10. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    Discontinued [GID-TA10851]

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    Discontinued [GID-TA10906]

    Technology appraisal guidance
    Discontinued

  12. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    Discontinued [GID-TA11357]

    Technology appraisal guidance
    Discontinued

  13. Pralsetinib for thyroid cancer [ID4018]

    Discontinued [GID-TA10910]

    Technology appraisal guidance
    Discontinued

  14. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    Discontinued [GID-HST10032]

    Highly specialised technologies guidance
    Discontinued

  15. LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

    Discontinued [GID-TA10728]

    Technology appraisal guidance
    Discontinued